Our Study, Our Voices

There are stark racial and ethnic differences in Alzheimer’s disease rates. Yet most research trials have not included enough participation of Black or African Americans, Latinos, Asian and Pacific Islanders, and American Indians and Alaska Natives.

Alzheimer’s clinical trial participation from diverse populations is critical because these groups are often at higher risk for developing the disease. The AHEAD Study aims to increase participation from underrepresented groups and needs individuals of every race and ethnicity to help find a treatment for Alzheimer’s disease that works for everyone.